Correction: Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer

Correction: Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/3/e010140corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
by: Jiaqi Zhao, et al.
Published: (2025-03-01)

Design and Characterization of Bispecific and Trispecific Antibodies Targeting SARS-CoV-2
by: Jiayang Wang, et al.
Published: (2025-02-01)

Trispecific SEED antibodies engineered for neutrophil-mediated cell killing
by: Veronica Natale, et al.
Published: (2025-12-01)

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses
by: Rui Qiao, et al.
Published: (2025-05-01)

Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer
by: Jeffrey S Miller, et al.
Published: (2025-07-01)

Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer
by: Yu‐Chuan Lin, et al.
Published: (2024-11-01)

Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2
by: Chaehyun Yum, et al.
Published: (2025-07-01)

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models
by: Ying Jin, et al.
Published: (2025-05-01)

Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
by: Tomasz Pienkowski, et al.
Published: (2025-03-01)

Leveraging HER2-targeted biparatopic antibodies in solid tumors
by: Xinlin Liu, et al.
Published: (2025-04-01)

Analysis of Tim-3 as a therapeutic target in prostate cancer
by: Yongrui Piao, et al.
Published: (2017-07-01)

HMGB1: A Promising Therapeutic Target for Prostate Cancer
by: Munirathinam Gnanasekar, et al.
Published: (2013-01-01)

Author Correction: Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy
by: Mohammad-Reza Nejadmoghaddam, et al.
Published: (2025-05-01)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
by: Ramesh Narayanan
Published: (2020-07-01)

Hydrogen Sulfide Signaling Axis as a Target for Prostate Cancer Therapeutics
by: Mingzhe Liu, et al.
Published: (2016-01-01)

Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers
by: Whi-An Kwon, et al.
Published: (2025-04-01)

Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
by: Isis Wolf, et al.
Published: (2025-01-01)

Innate immunity, therapeutic targets and monoclonal antibodies in SARS-CoV-2 infection
by: Mubashir Nazir, et al.
Published: (2025-06-01)

Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression
by: Bohong Chen, et al.
Published: (2024-09-01)

Targeting the brain-gut-prostate axis in chronic prostatitis: mechanisms and therapeutics
by: Shiwei Song, et al.
Published: (2025-07-01)

Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer
by: Chia-Hsien Shih, et al.
Published: (2025-03-01)

Exploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer
by: Xiao-xiang Yu, et al.
Published: (2025-02-01)

Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
by: Hao Liang, et al.
Published: (2025-12-01)

Integrin‐Targeted, Activatable Nanophototherapeutics for Immune Modulation: Enhancing Photoimmunotherapy Efficacy in Prostate Cancer Through Macrophage Reprogramming
by: Cheng Zhang, et al.
Published: (2025-05-01)

Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
by: Sarah Jurmeister, et al.
Published: (2018-02-01)

New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic
by: Maoping Cai, et al.
Published: (2025-01-01)

Role of SIRT7 in Prostate Cancer Progression: New Insight Into Potential Therapeutic Target
by: Jiale Zhang, et al.
Published: (2025-04-01)

Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models
by: Syeda Afshan, et al.
Published: (2024-09-01)

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy
by: Huihui Guo, et al.
Published: (2025-02-01)

Precision targeting of androgen receptor–ferroptosis crosstalk in prostate cancer: From mechanisms to therapeutic strategies
by: Dongfang Lv, et al.
Published: (2025-09-01)

Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents
by: Azura Murphy, et al.
Published: (2025-03-01)

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors
by: Xiong Zhang, et al.
Published: (2025-03-01)

Targeting Methionine Metabolism Reveals AMPK-SAMTOR Signaling as a Therapeutic Vulnerability in Prostate Cancer
by: Serdar Arisan, et al.
Published: (2025-05-01)

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
by: Qi Shen, et al.
Published: (2024-12-01)

Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer
by: Yankui Liu, et al.
Published: (2025-02-01)

Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer
by: Weijie Zhang, et al.
Published: (2024-09-01)

Enhancing diagnostic innovation by leveraging the co-creation approach
by: Jochen K. Lennerz, et al.
Published: (2025-08-01)

Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy
by: Amaury Herbet, et al.
Published: (2025-01-01)

Unlocking the therapeutic potential of antibody–drug conjugates in targeting molecular biomarkers in non-small cell lung cancer
by: Shruti Soni, et al.
Published: (2025-03-01)

Therapeutic Antibodies for the Treatment of Pancreatic Cancer
by: Patrick Chames, et al.
Published: (2010-01-01)